期刊文献+

A771726在大鼠体内的药代动力学 被引量:2

Pharmacokinetics of A771726 in rats
下载PDF
导出
摘要 目的研究A771726在大鼠体内的药代动力学过程。方法单剂量口服给药3个剂量的A771726,根据大鼠体内血药浓度经时过程,计算相应的药代动力学参数。结果A771726(3、6、12mg/kg)的血药经时过程均符合一级吸收的一房室模型,其主要药动学参数T1/2Ka(h):3.91±3.43、5.63±2.07、6.73±1.67;T1/2Ka(h):17.45±10.79、9.68±4.65、7.63±1.39;AUCm。)(mg/L·h^-1):163.83±17.88、447.88±148.60、843.72±175.41;Cmax(mg/L):7.05±1.17、24.00±1.87、39.93±3.90;Tmax(h):8.00±0.00、6.67±2.06、8.00±0.00;MRT(0-m)(h):19.87±4.25、19.54±1.11、19.29±2.47。结论单剂量口服A7717263个剂量组的药物代谢均成线性关系,其血药浓度-时间曲线符合一级吸收的一房室模型。 Objective To study the pharmacokinetics of A771726 in rats. Methods A single oral dose of A771726 (3, 6, 12 mg/kg)was performed in SD rats, then the corresponding pharmacokinetic parameters based on the time process of blood drug concentration were calculated. Results The blood plasma CoL curve of A771726 conformed to one compartment model of the first order absorption. The main pharmacokinetie parameters of A771726(3, 6, 12 mg/kg) were T1/2Ka ( h ) : 3.91 ± 3.43, 5.63 ± 2.07, 6. 73± 1.67 ; T1/2Ka ( h ) : 17.45 ± 10. 79, 9.68 ± 4.65, 7.63±1.39; AUC(0-m)(mg·h/L): 163.83±17.88,447.88±148.60, 843.72±175.41; Cmax(mg/L): 7.05 ±1. 17, 24.00±1.87, 39.93 ±3.90; Tmax (h): 8.00±0.00, 6.67±2.06, 8.00±0.00; MRT(0-m)(h): 19. 87 ±4.25, 19.54 ± 1. 11 , 19. 29±2.47. Conclusion The metabolism of A771726 following oral administration accords with the linear relation, and its blood plasma Cot curve consists with the first order kinetics of one compartment model.
出处 《安徽医科大学学报》 CAS 北大核心 2007年第2期192-194,共3页 Acta Universitatis Medicinalis Anhui
基金 安徽省教育厅自然科学基金项目(编号:2004kj196) 安徽医科大学博士基金项目(2005年)
关键词 色谱法 高压液相 异恶唑类/药代动力学 异恶唑类/投药和剂量 A771726 chromatography,high pressure liquid isoxazoles/pharmacokinetics isoxazoles/administration and dosage A771726
  • 相关文献

参考文献6

二级参考文献26

  • 1[1]Bruneau JM, Yea CM, Spinella-Jaegle S, et al. Purification of human dihydro -orotate dehydrogenase and its inhibition by A771726, the active metaboli te of leflunomide[J]. J Biochem,1998, 336 (2):299. 被引量:1
  • 2[2]Xu X, Blinder L, Shen J, et al. In vivo mechanism by which leflunomide contr ols lymphoproliferative and autoimmune disease in MRL/MpJ-Ipr/Ipr mice[J]. J Immunol,1997,159(1):167. 被引量:1
  • 3[3]Elder RT, Xu X, Wlliams JW, et al. The immunosuppressive metabolite of leflu nomide, A771726, affects murine T cells through two biochemical mechanisms [J]. J Immunol,1997,159(1):22. 被引量:1
  • 4[4]Dias VC, Lucien J, Legatt DF, et al. Measurement of the active leflunomid e m etabolite (A771726) by reverse-phase high-performance liquid chromatogra phy[J]. Ther Drug Monit,1995, 17(1):84. 被引量:1
  • 5[5]Chong AS, Huang WY, Liu W, et al. In vivo activity of leflunomide: Pharmacok inetic analyses and mechanism of immunosuppression[J]. Transplantation,1999, 6 8(1): 100. 被引量:1
  • 6Schorlemmer H U, Milbert U, Zitter D, et al. Cell cycle regulation and inhibition of de novo pyrimidine biosynthesis by leflunomide[J]. Inflamm Res, 1999, 48(Suppl 2) :115 -6. 被引量:1
  • 7Kale Vijay P, Bichile L S. Leflunomide: A novel disease modifying anti-rheumatic drug[J]. J Postgrad Med, 2004, 50(2) : 154 -7. 被引量:1
  • 8Tlacuilo-Parra J A, Guevara-Gutierrez E, Rodriguez-Castellanos M A, et al. Leflunomide in the treatment of psoriasis: results of aphase Ⅱ open trial[J]. Br J Dermatol, 2004, 150(5) : 970 -6. 被引量:1
  • 9Schmitt J, Wozel G. Psoriasis arthritis-long-term treatment of two patients with leflunomide [ J ]. J Dtsch Dermatol Ges, 2004, 2(9) : 763 -6. 被引量:1
  • 10Walsh S R A, Shear N H. Psoriasis and the new biologic agents:interrupting a T-AP dance[J]. CMAJ, 2004, 170(13) : 1933 -41. 被引量:1

共引文献25

同被引文献12

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部